Kornimate/medical-research-clean huggingface dataset:
effect of instrument assisted soft tissue mobilization and dynamic cupping

Conditions: Fractures, Bone

Summary: children who experience fractures may develop stiffness and limited range of motion in their affected joints, notably the elbow. although conventional rehabilitation approaches have demonstrated some effectiveness, innovative methods like instrument assisted soft tissue mobilization (iastm) and dynamic cupping hold promise for enhancing outcomes. these techniques represent emerging therapies aimed at improving range of motion and function across different musculoskeletal conditions. however, there is a lack of comparative research examining their efficacy specifically in pediatric patients with post-fracture elbow stiffness

this will be a randomized clinical trial conducted on 28 participants. data will be collected from khatoon e jannat hospital, mujahid hospital and children hospital of faisalabad. the study includes children aged 6 to 15, both genders, experiencing elbow postoperative stiffness and with a loss of extension of at least -30 degrees and/or flexion of no more than 120 degrees. participants excluded from the study are those who declined consent, had pathological fractures, and associated ipsilateral injuries, bilateral upper extremity injuries, neuro-vascular disorders, heterotrophic ossification, or contraindications for iastm. a sample of 28 will be divided in to two groups. each group will consist of 14 participants. group a will receive instrument assisted soft tissue mobilization. on the contrary group b will receive dynamic cupping therapy. both groups will be given conventional therapy along with prescribed intervention. intervention will be given for 30 minutes for 3 sessions per week for 4 weeks. data will be collected before and after the intervention to assess range of motion and function with a help of goniometer and disability arm shoulder and hand questionnaire. data will be analyzed by using spss version 26.0

Eligibility criteria:
inclusion criteria * age from 6 to 15 years (23) * both genders participant with elbow postoperative stiffness with loss of extension of ≥-30 degrees and/or flexion ≤120 degrees participant with at least 6-week post-surgery with open reduction and internal fixation done for either of the following fractures. exclusion criteria: * participants who declined consent. * participants who had pathological fractures, associated ipsilateral injuries, bilateral upper extremity injuries, neuro-vascular disorders, heterotrophic ossification, and contraindications for iastm

Keywords: elbow post fracture stiffness
drum circle synchrony study 2c.a.

Conditions: Mental Health Issue; COVID-19

Summary: mental health vulnerability due to stress is increased in people of african descent (pads) in america due to disproportionate effects of racism, poverty, education, and criminal justice sentencing. various meditation and mindfulness approaches have provided evidence of measured reductions in multiple negative dimensions of stress. however, the majority of these studies do not have an adequate representation of pads or other marginalized groups and are not designed to be culturally relevant or community based. music has been shown to alleviate multiple symptoms of stress and has been shown to be a preferred and effective support for meditation and mindfulness. however, its role in stress management in pads engaged in meditation or mindfulness is seldom studied. this study aims to evaluate the effects of a virtual, community-based music mindfulness program on stress management in pad community members with anxiety and depression during covid19. 2c.a. drum circle synchrony study: this study will investigate the role that synchrony plays in subjective feelings of connection.

the investigators also propose a study to investigate the effects of communal drumming in reducing anxiety and increasing connectedness within drum circle community. investigators hypothesize that these intervention will lead to reductions in scores on stress scales and will provide preliminary data for studies evaluating these types of community programs as an adjunct to the standard of care. musicians and non-musicians will listen to segments (\~30 sec duration) of recordings taken from the music made during a previous arm of drum circle and answer a survey. segments will be categorized as highly synchronized or not synchronized.

Eligibility criteria:
inclusion criteria: * ages 18 and older exclusion criteria: * ages 17 and younger

Keywords: mindfulness meditation music
abdominal fat and imaging measurements of heart disease

Conditions: Visceral Obesity; Atherosclerosis; Metabolic Syndrome

Summary: although it is frequently mentioned in the media that overweight and obesity have reached epidemic proportions worldwide and in this country, some canadians are perplexed and sometimes confused about the role of obesity in diabetes and heart disease. in fact, the investigators even hear from time to time that there could be "healthy" obese individuals. in clinical practice, assessment of obesity as a risk factor for cardiovascular disease (cvd) remains a challenge as even some physicians are confused. however, studies conducted in our laboratory and by other research teams around the world over the last 20 years have clearly shown that body shape is more important than body size when evaluating the risk of overweight/obesity and that high accumulation of abdominal fat (excess belly fat) increases the risk of diabetes and cardiovascular disease (cvd). the investigators now need to better understand the link between excess belly fat and atherosclerosis (the thickening of artery walls by fatty deposits, also referred to as atherosclerotic plaque), leading to complications such as angina (chest pain) and myocardial infarction (heart attacks). using non-invasive imaging techniques such as magnetic resonance imaging, the investigators therefore propose to examine the relationships between measures of fatness and of abdominal fat and the size of atherosclerotic plaque in large blood vessels of apparently healthy human subjects. this study is also a unique opportunity to look, for the first time, at the relationship between belly fat, blood sugar, several well-known risk factors for heart disease (cholesterol, blood pressure, cardiorespiratory fitness, etc.) and the size of atherosclerotic plaques. this research program should pave the way to the development of new improved preventive/therapeutic approaches focusing not on body weight but rather on abdominal fat and associated blood abnormalities which are predictive of the development of atherosclerotic plaques leading to the premature development of heart disease.


Eligibility criteria:
inclusion criteria: * men and women aged 35-65 years exclusion criteria: * massive obesity (bmi ≥ 40 kg/m2) * pharmacological treatment for lipids, hypertension and/or type 2 diabetes * clinical signs of cardiovascular disease * chronic inflammatory or auto-immune diseases * pulmonary diseases on corticosteroids * cancers not in remission * history or clinical evidence of coronary heart disease (chd) * history of revascularisation procedures * current smoking * hormonal replacement therapy

Keywords: visceral obesity cardiometabolic risk atherosclerosis ectopic fat carotid plaque magnetic resonance imaging (mri) computed tomography (ct)
cardiovascular outcomes of diet counseling

Conditions: Coronary Artery Disease; Obesity

Summary: (1) what effect does behavioral counseling for vegan, for low to moderate fat, and for lowered carbohydrate diets have on coronary blood flow? (2) what are the effects of different diet protocols when caloric intake and exercise are equalized? (3) do people, so counseled, maintain their modified behaviors after they have completed their diet program? (4) how does targeting different diets affect secondary indices associated with heart disease such as weight, lipid, inflammatory, and thrombotic factors?

given the current epidemic of overweight and obesity on a global scale ("globesity") and the consequent world public health objective of reducing that obesity, it is evident as a practical matter that, the main line of attack must be through diet. the public health objective and the lack of information regarding the long-term public health effects of alternative weight-loss diets motivated this comparative study of the three major types of weight-loss diets and their long term effects on coronary blood flow. secondary endpoints are inflammatory and other variables associated with heart disease and obesity. specifically we asked: (1) what effect does behavioral counseling for vegan, for low to moderate fat, and for lowered carbohydrate diets have on coronary blood flow? (2) what are the effects of different diet protocols when caloric intake and exercise are equalized? (3) do people, so counseled, maintain their modified behaviors after they have completed their diet program? (4) how does targeting different diets affect secondary indices associated with heart disease such as weight, lipid, inflammatory, and thrombotic factors?

Eligibility criteria:
inclusion criteria: bmi greater than 30, exclusion criteria: pre-existing co-morbid diseases (documented heart disease, diabetes mellitus, cancer, hypertension, hepatic, renal or gastrointestinal disease), pregnancy or plans for pregnancy. participants could not be smokers (cigarettes, cigars, pipes or chewing tobacco), take medications (prescription or over the counter medications with the exception of antibiotics), nor take vitamin or mineral supplements. additionally, they could not currently be on a diet or have been on one during the last 6 months, or have food allergies that would influence food choices.

Keywords: obesity diets heart disease randomized controlled trial ischemia.
study to assess the pharmacodynamics/pharmacokinetics after repeated dosing of d961h 10 mg and omeprazole 10 mg in japanese healthy male subjects

Conditions: Pharmacodynamics Study

Summary: the purpose of this study is to assess the pharmacodynamics (intragastric ph) after repeated oral administration of d961h 10 mg and omeprazole 10 mg in japanese healthy male subjects who are classified by the genotype of cyp2c19 by the assessment of percentage of time with intragastric ph\>4 during 24 hours after dose on day 5.


Eligibility criteria:
inclusion criteria: * healthy japanese male subjects between 20 and 45 years of age * genotype of cyp2c19 has been known as the volunteer panel data * h. pylori negative has been known by urea breath test as the volunteer panel data. exclusion criteria: * significant clinical illness from the 2 weeks preceding the pre-entry visit to the randomisation, as judged by the investigator(s), eg, acute inflammatory disease which requires medical intervention * past or present cardiac, renal, hepatic, neurological or gastrointestinal disease, as judged by the investigator(s), eg, sequelae of myocardial infarction, nephritis, hepatitis and cerebral infarction * past or present severe allergic disease, hypersensitivity to food or drugs (except for seasonal hay fever), or allergic symptoms requiring medical intervention (eg, anesthetics used at the intragastric ph measurement)

Keywords: healthy volunteer japanese males homo-em/hetero-em/pm
a comparison of two electronic gloves in the measurement of joint movement in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: in this study we will compare two electronic goniometric gloves to see if they can be used in research on joint movement in arthritis. one of the gloves we will use is the commercially available '5dt ultra 14 glove', the other is a glove that we have specially designed and developed for use in people with arthritis. both gloves are 'high-end' gloves with sensors for all of the finger and thumb joints. we aim to find out if the gloves are accurate and if they can be worn and used without too much discomfort by people with arthritis.

this is an open pilot study to assess the usability and accuracy of two electronic goniometric gloves in measuring finger joint movement in patients with rheumatoid arthritis. we will use questionnaires to assess pain, stiffness and disability. we will be using an inner disposable glove worn under the electronic goniometric gloves as this will be important for infection control in clinical use. we will calibrate the electronic goniometric gloves using wooden blocks at predefined angles using our own software calibration process to optimise the accuracy of the glove for the individual patient. the patient will flex and extend their fingers repeatedly to get measurements of the minimum and maximum angle of flexion in their joints. during these movements we will also capture the dynamic characteristics of movement such as maximum velocity. in this study a laptop will be used to capture and record all of the measurements from the electronic goniometric glove and record the time at which the measurements were taken. each electronic goniometric glove will be refitted for a second set of tests to assess variability due to the fitting process. we will record a full set of data from each set of movements for later analysis. finally, we will assess usability and establish if patients have a preference between the two electronic goniometric gloves.

Eligibility criteria:
inclusion criteria: * male and female patients aged 18 to 80 * diagnosis of rheumatoid arthritis * patients who have significant pain and stiffness in their hands * correct hand size to achieve a good fit to the electronic goniometric glove exclusion criteria: * poor fit for the disposable surgical glove * severe pain in the right hand * severe swelling in the right hand (rated as such by the investigator) * major permanent deformities in the right hand * active hyperextension \>30 degrees in any joint of the right hand * broken or infected skin in the right hand * known to have tested positive for methicillin resistant staphylococcus aureus (mrsa) skin infections in the past * unable to don the lining disposable glove without significant discomfort * history of latex allergy

Keywords: arthritis rheumatoid joints swelling measurement movement electronic data glove goniometry outcome stiffness
efficacy and safety of flexibly dosed bms-820836 in the treatment of patients with treatment resistant major depression

Conditions: Depression

Summary: the purpose of the study is to evaluate the efficacy of study drug (bms-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (trd).


Eligibility criteria:
inclusion criteria: * patients must be able to understand the nature of the study, agree to comply with the prescribed dosage regimens, report for regularly scheduled office visits, and communicate to study personnel about adverse events and concomitant medication use. * patients with a diagnosis of major depressive disorder, currently experiencing a major depressive episode, as defined by diagnostic and statistical manual of mental disorders- fourth edition text revision(dsm iv tr) criteria. the current depressive episode must be \> 8 weeks in duration and \< 3 years duration. * in the current major depressive disorder (mdd) episode, patients should report a history of inadequate response to 1 - 3 adequate trials of antidepressant treatment. * patients must have a 17-item hamilton depression rating scale (ham-d17) total score =\>18 at screening. exclusion criteria: * patients who report an inadequate response (less than 50% reduction in depressive symptom severity) to more than three adequate trials of antidepressant treatments during the current depressive episode. * patients who have failed duloxetine at an adequate dose and for an adequate duration in their current episode unless in the judgment of the investigator, the patient could benefit from the treatment with this medication. * patients whose only inadequate response to an antidepressant in the current major depressive episode (mde) is to an serotonin norepinephrine reuptake inhibitors (snri) (duloxetine, venlafaxine, desvenlafaxine or milnacipran).
gastro-oesophageal reflux in oligosymptomatic patients with dental erosion

Conditions: Dental Erosion; Gastroesophageal Reflux

Summary: dental erosions, the chemical dissolution of enamel without bacterial involvement, are considered to be an established complication of gastroesophageal reflux disease (gerd) by the montreal global consensus statement. given the high prevalence of dental erosions and the absence of any ph-impedance data or medical management guidelines for gerd-associated dental erosions, reflux characteristics will be characterized using questionnaires, endoscopy and esophageal ph-impedance testing, in successive patients dental erosions referred by dentists for evaluation of gerd. for assessment of the role of additional factors besides h+ activity in the refluxate, a sample of gastric juice will be aspirated during endoscopy and frozen for analysis of pepsin and other proteases. prognostic factors for progression of dental erosions will be determined by repeating the evaluation after chronic dosing with esomeprazole 20mg twice-daily, which is prescribed to all patients.


Eligibility criteria:
inclusion criteria: * successive male and female patients * over 18 years of age presenting to the university of bern department of dentistry and affiliated dentists * dental erosions exclusion criteria: * non-reflux causes of erosion * reduced salivary flow and buffering capacity * history of bruxism, eating disorders, recurrent vomiting, severe obesity (bmi\>35kg/m2) or past bariatric surgery * dietary or abrasive causes for dental erosion
dose escalation study of valortim® (mdx-1303) administered intravenously (iv) in healthy, normal subjects

Conditions: Anthrax

Summary: valortim is the name of the experimental drug that volunteers will receive in this study. valortim may also be called mdx-1303. experimental means that the drug is not yet approved by the food and drug administration (fda). valortim is a monoclonal antibody (laboratory-made immune system molecule) for the treatment of inhalation anthrax (when the infection starts in the lungs). valortim works by attaching itself to part of the anthrax toxin preventing the toxin from doing damage to cells. this study is being conducted to see if valortim given over 120 minutes is safe and tolerable. this study will take place in five parts: screening phase, check-in phase (the day you arrive at quintiles to start the study), treatment phase (the time when you receive the study medication), follow-up phase (the time after you receive the study medication) and final visit.

twenty-eight subjects will be recruited and entered into one of three dose groups 1mg/kg, 5mg/kg, 10mg/kg or placebo. subjects will be stagger dosed into one of the three groups and randomly assigned to receive valortim or saline. subjects will reside in the clinical trial phase i unit from day -1 through day 2. after discharge on day 2, all subjects will return to the phase i unit 7 times at specified time points over an additional 130 days post-dosing (133 days total participation from check-in on day -1)or placebo.

Eligibility criteria:
inclusion criteria: 1.subject must have read, understood, and provided written informed consent 2.subjects should be in generally good health, based upon pre-study medical history, physical examination, laboratory testing and ecg 3.laboratory screening values (i.e., hematology, clinical chemistries and urinalysis tests) must be within study-defined ranges 4.no detectable antibody to b. anthracis protective antigen (pa-igg) as measured by elisa testing at study screening 5.women of childbearing potential and sexually active males may be enrolled if protocol specific contraceptives or practices are met 6.agreement to not receive any vaccinations day -1 through to 29 days post dosing. vaccination against b. anthracis is prohibited during the study.8.body mass index (bmi) ≥ 19 and ≤ 30. 9. abstinence from alcohol for 24 hours prior to study drug exclusion criteria: 1. prior known or suspected exposure to b. anthracis 2. prior vaccination for b. anthracis 3.prior exposure to valortim as part of a previous clinical trial 4.immunoglobulin e (ige) level at screening that is above the upper limit of normal per the laboratory's reference range 5. history of drug or alcohol abuse, i.e., having been treated either in an in-patient or out-patient facility within 12 months of study screening 6. outward signs of active allergies or upper respiratory infection 7. history of dizziness or fainting upon standing (orthostatic hypotension) which, in the opinion of the investigator, may interfere with safety evaluations 8. positive drug result and/or positive alcohol result at time of study screening or at day -1

Keywords: phase i
evaluation of the efficacy and safety of al2846 capsule combined with tqb2450 injection compared to docetaxel injection in advanced non-small cell lung cancer patients who have failed with immunotherapy.

Conditions: Non-small Cell Lung Cancer

Summary: to investigate the efficacy of al2846 capsules in combination with tqb2450 injection or docetaxel injection in patients with advanced nsclc who have previously failed immune checkpoint inhibitors (anti-pd-1 monoclonal antibody, anti-pd-l1 monoclonal antibody), regardless of new anti-tumor treatment and early termination of treatment.


Eligibility criteria:
inclusion criteria: * the subjects voluntarily joined the study, signed an informed consent form, and had good compliance * age: 18-75 years; eastern eastern cooperative oncology group performance status (ecog ps) score: 0-1; bmi ≥ 17 at baseline; * patients with histologically or cytologically confirmed inoperable and inoperable locally advanced (stage iiib/iiic), metastatic or recurrent (stage iv) nonsmall-cell lung cancer (nsclc) who cannot receive radical concurrent chemoradiotherapy; * failure of platinum-based chemotherapy and immune checkpoint inhibitors for incurable locally advanced or metastatic or recurrent nsclc; * number of lines of prior systemic therapy received for locally advanced or metastatic/recurrent disease that is unresectable/not amenable to radical chemoradiation; * confirmed to have at least one measurable lesion according to response evaluation criteria in solid tumours（ recist 1.1） standard; * adequate major organ function; exclusion criteria: * patients who have been diagnosed or currently had other malignant tumors; * presence of epidermal growth factor receptor (egfr) mutation, anaplastic lymphoma kinase (alk) fusion, c-ros oncogene 1 (ros1) fusion and other significant driver gene mutations; * factors affecting oral drugs; * major surgical treatment, incisional biopsy or obvious traumatic injury and long-term uncured wound or fracture within 28 days before the start of study treatment; * hyperactive/venous thrombotic events within 6 months; * subjects with any severe and/or uncontrolled disease; * previously received other immunotherapy and research advance of small molecular targeted anti-tumor agents tyrosine kinase inhibitors (tkis); * according to the investigator's judgment, there are concomitant diseases that seriously endanger the subject's safety or affect the completion of the study, or there are other reasons that are not suitable for the subject;